Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nonmyeloablative Allogeneic PBSCT for High Risk ALL
NCT00031655Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Sep 2001
- Primary completion
- Aug 2006
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of peripheral blood stem cells in acute lymphoblastic leukemia (ALL), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Disease-Free Survival at 1 year. Started Sep 2001; status: completed.
02
Drugs
peripheral blood stem cells
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00031655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00031655.